5. Design Platforms of Nanocapsules for Human Therapeutics or Vaccines

  1. Manmohan Singh and
  2. Indresh K. Srivastava
  1. Masaaki Kawano1,
  2. Li Xing1,
  3. Kit S. Lam2,
  4. Hiroshi Handa3,
  5. Tatsuo Miyamura4,
  6. Susan Barnett5,
  7. Indresh K. Srivastava5 and
  8. R. Holland Cheng1

Published Online: 6 JUN 2011

DOI: 10.1002/9781118023648.ch5

Development of Vaccines: From Discovery to Clinical Testing

Development of Vaccines: From Discovery to Clinical Testing

How to Cite

Kawano, M., Xing, L., Lam, K. S., Handa, H., Miyamura, T., Barnett, S., Srivastava, I. K. and Cheng, R. H. (2011) Design Platforms of Nanocapsules for Human Therapeutics or Vaccines, in Development of Vaccines: From Discovery to Clinical Testing (eds M. Singh and I. K. Srivastava), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118023648.ch5

Editor Information

  1. Novartis Vaccines, Cambridge, Massachusetts, USA

Author Information

  1. 1

    University of California at Davis, Davis, California, USA

  2. 2

    University of California at Davis Cancer Center, Sacramento, California, USA

  3. 3

    National Institute of Infectious Diseases, Tokyo, Japan

  4. 4

    Tokyo Institute of Technology, Yokohama, Japan

  5. 5

    Novartis Vaccines, Cambridge, Massachusetts, USA

Publication History

  1. Published Online: 6 JUN 2011
  2. Published Print: 18 JUL 2011

ISBN Information

Print ISBN: 9780470256374

Online ISBN: 9781118023648

SEARCH

Keywords:

  • nanocapsule design platform, human therapeutics - virus-like particles (VLPs), clinical use;
  • tailoring VLPs, capsid surface alteration - genetic fusion, immunogenic epitopes of other pathogens;
  • viral capsids, potential nanocarriers - biologically active materials, for specific cell types

Summary

This chapter contains sections titled:

  • Application of Virus-Like Particles for Vaccination

  • Innate and Adaptive Cellular Immune Responses Against Virus-Like Particles

  • Tailoring Virus-Like Particles by Altering the Capsid Surface for Vaccine Development

  • Use of Fluorescent-Labeled Virus-Like Particles to Isolate Rotavirus-Specific B-Cell Clones for Human Monoclonal Antibody Production

  • VLP Application as a Delivery Carrier

  • Conclusion

  • References